Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed univariate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan?Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p?
Alkuperäiskielienglanti
Artikkeli1010428319860728
LehtiTumor Biology
Vuosikerta41
Numero7
Sivumäärä10
ISSN1010-4283
DOI - pysyväislinkit
TilaJulkaistu - 2 heinäkuuta 2019
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3122 Syöpätaudit

Lainaa tätä

@article{9f2fa0d575ac4c989b90232cce650287,
title = "Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay",
abstract = "Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed univariate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan?Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p?",
keywords = "3122 Cancers",
author = "Kajsa Bj{\"o}rkman and Harri Mustonen and Tuomas Kaprio and Caj Haglund and Camilla B{\"o}ckelman",
year = "2019",
month = "7",
day = "2",
doi = "10.1177/1010428319860728",
language = "English",
volume = "41",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "SAGE Publications Ltd STM",
number = "7",

}

Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay. / Björkman, Kajsa; Mustonen, Harri; Kaprio, Tuomas; Haglund, Caj; Böckelman, Camilla.

julkaisussa: Tumor Biology, Vuosikerta 41, Nro 7, 1010428319860728, 02.07.2019.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay

AU - Björkman, Kajsa

AU - Mustonen, Harri

AU - Kaprio, Tuomas

AU - Haglund, Caj

AU - Böckelman, Camilla

PY - 2019/7/2

Y1 - 2019/7/2

N2 - Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed univariate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan?Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p?

AB - Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed univariate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan?Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p?

KW - 3122 Cancers

U2 - 10.1177/1010428319860728

DO - 10.1177/1010428319860728

M3 - Article

VL - 41

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 7

M1 - 1010428319860728

ER -